Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Condition: IDH1-mutant Cholangiocarcinoma Interventions: Drug: Ivosidenib; Drug: Recommended Combination Dose (RCD) of ivosidenib; Drug: Nivolumab; Drug: Ipilimumab Sponsors: Servier Bio-Innovation LLC; Institut de Recherches Internationales Servier Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials